The trend towards personalized medicine is omnipresent: more and more innovative drugs depend on an upfront diagnosis of biomarkers to ensure safe and effective therapy. The search for viable markers thus increasingly becomes an integral part of modern drug development.
regenold GmbH is specialized in pharmaceutical products as well as medical devices with our CEplus division and therefore we are optimally prepared to support the (co-)development of Companion Diagnostics (CDx) both for developers of diagnostics as well as pharmaceutical companies. Having access to a vast network of partners and clients enables us to also help you identifying potential partners for the development of your CDx.
We are very proud about having supported our clients in successfully CE marking their Companion Diagnostics.